Gushyalatha Boya, MD
Internal Medicine · Cedar Park, TXNPI 1679777270
Payments from drug & device makers
Across 161 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$375
- Novo Nordisk$291
- AstraZeneca$229
- Amgen$215
- GSK$197
- AbbVie$167
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,860100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 21 | $375 |
| Novo Nordisk | 14 | $291 |
| AstraZeneca | 16 | $229 |
| Amgen | 14 | $215 |
| GSK | 17 | $197 |
| AbbVie(2 entities) | 9 | $167 |
| Radius Health, Inc. | 6 | $145 |
| Abbott | 6 | $140 |
| Lilly USA, LLC | 8 | $126 |
| Xeris Pharmaceuticals, Inc. | 5 | $100 |
| Medtronic | 1 | $96 |
| Astellas Pharma US Inc | 4 | $70 |
| Amarin Pharma, Inc. | 4 | $61 |
| Merck | 3 | $55 |
| Viiv Healthcare Company | 2 | $52 |
| BETA Bionics, Inc. | 2 | $37 |
| Recordati_rare_diseases_inc. | 2 | $37 |
| Corcept Therapeutics | 2 | $36 |
| Bayer | 2 | $35 |
| Pfizer | 2 | $34 |
| Insulet Corporation | 2 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Dynavax Technologies Corporation | 2 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| Stryker | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Aytu Biopharma, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$2,860 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 102 | $135,640 |
| JardianceEmpagliflozin | 67 | $102,897 |
| JanuviaSitagliptin Phosphate | 51 | $74,336 |
| MounjaroTirzepatide | 49 | $65,867 |
| EliquisApixaban | 43 | $37,236 |
| TradjentaLinagliptin | 20 | $24,720 |
| TrulicityDulaglutide | 13 | $22,343 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $20,514 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $20,031 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $9,167 |
| Mirabegron ErMirabegron | 14 | $8,823 |
| MyrbetriqMirabegron | 11 | $8,782 |
| SynthroidLevothyroxine Sodium | 72 | $5,852 |
| Levothyroxine Sodium | 384 | $5,696 |
| Rosuvastatin Calcium | 252 | $5,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $375 | $148,131105 claims |
| Novo NordiskOzempic | $291 | $135,640102 claims |
| MerckJanuvia, Janumet Xr | $55 | $94,36867 claims |
| Lilly USA, LLCMounjaro, Trulicity | $126 | $88,21062 claims |
| PfizerEliquis, Paxlovid | $34 | $40,09457 claims |
| Astellas Pharma US IncMyrbetriq | $70 | $8,78211 claims |
| AbbVieSynthroid | $167 | $5,85272 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $5,696384 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Cedar Park
- Mark CarlsonCedar Park$6.6M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.